Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

References

• Call T G, Phyliky R L, Noel P, Habermann T M, Beard C M, O'Fallon W M, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 1994; 69: 323–328
   PubMed Web of Science ®Google Scholar
• Apelgren P, Hasselblom S, Werlenius O, Nilsson-Ehle H, Andersson P O. Evaluation of clinical staging in chronic lymphocytic leukemia-population-based study. Leuk Lymphoma 2006; 47: 2505–2516
   PubMed Web of Science ®Google Scholar
• Diehl L F, Karnell L H, Menck H R. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86: 2684–2692
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Bosch F, Muntanola A, Gine E, Carrio A, Villamor N, Moreno C, et al. Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia. Cytometry B: Clin Cytom 2006; 70: 214–217
   PubMed Web of Science ®Google Scholar
• Del Principe M I, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006; 108: 853–861
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Orchard J A, Ibbotson R E, Davis Z, Thomas P W, Stevenson F K, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023–1029
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Keating M, Do K A, O'Brien S, Huh Y O, Jilani I, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181–186
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno A M, Capelli G, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633–2639
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Dewald G W, Brockman S R, Paternoster S F, Bone N D, O'Fallon J R, Allmer C, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 121: 287–295
   PubMed Web of Science ®Google Scholar
• Jelinek D F, Tschumper R C, Geyer S M, Bone N D, Dewald G W, Hanson C A, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001; 115: 854–861
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Witzig T E, Fink S R, Jenkins R B, Paternoster S F, Smoley S A, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634–4641
   PubMed Web of Science ®Google Scholar
• Therneau T, Grambasch P. Modeling Survival Data: Extending the Cox Model. Springer, New York 2000
   Google Scholar
• Therneau T, Offord J. Technical Report Number 63: Expected Survival Based on Hazard Rates. Mayo Clinic. 1999; 1–26
   Google Scholar
• Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia?. Haematologica 2001; 86: 8–12
   PubMed Web of Science ®Google Scholar
• Rozman C, Bosch F, Montserrat E. Chronic lymphocytic leukemia: a changing natural history?. Leukemia 1997; 11: 775–778
   PubMed Web of Science ®Google Scholar
• Rai K R, Sawitsky A, Cronkite E P, Chanana A D, Levy R N, Pasternack B S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Wierda W G, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do K A, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukmeia. Blood 2007; 109: 4679–4685
   PubMed Web of Science ®Google Scholar